Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $251

Morgan Stanley maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $250 to $251.

Benzinga · 01/31/2020 16:07

Morgan Stanley maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $250 to $251.